Corvus (CRVS) director awarded options for 15,000 shares at $11.60

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Corvus Pharmaceuticals director Richard van den Broek received a new stock option grant. On the reported date, he was awarded options to buy 15,000 shares of Corvus common stock at an exercise price of $11.60 per share. All 15,000 options vest in a single tranche on the earlier of the first anniversary of the grant or the company’s 2027 annual stockholder meeting, assuming he continues serving as a director until that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider van den Broek Richard

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 15,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 15,000 options Exercise price: $11.60 per share Underlying shares: 15,000 shares +2 more

5 metrics

Option grant size 15,000 options Stock Option (Right to Buy) awarded to director

Exercise price $11.60 per share Conversion or exercise price of granted options

Underlying shares 15,000 shares Common Stock underlying the option grant

Expiration date 2036-06-11 Option expiration for the 15,000-share grant

Shares following transaction 15,000 options Total derivative securities after this award

Key Terms

Stock Option (Right to Buy), exercise price, underlying security, Annual Meeting of the Issuer's stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "11.6000" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: "Common Stock" with 15,000 shares"

Annual Meeting of the Issuer's stockholders regulatory

"earlier of the first anniversary or the 2027 Annual Meeting"

vesting financial

"shares subject to the option vest and become exercisable as to 100%"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 05:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van den Broek Richard

(Last)

(First)

(Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$11.6	06/11/2026		A		15,000		⁽¹⁾	06/11/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Leiv Lea, as Attorney-in-Fact for Richard van den Broek	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Corvus Pharmaceuticals (CRVS) director Richard van den Broek receive in this Form 4?

He received a stock option grant for 15,000 shares of Corvus common stock. The options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the new Corvus (CRVS) stock options?

The options have an exercise price of $11.60 per share for 15,000 underlying common shares. This price is the cost per share he must pay to exercise the options once they are vested and exercisable, according to the Form 4 disclosure.

When do Richard van den Broek’s new Corvus (CRVS) options vest?

The 15,000 options vest 100% on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting. Vesting is contingent on his continuous service as a director through that vesting date, as described in the footnote.

Is this Corvus (CRVS) Form 4 an insider stock purchase or a compensation award?

This filing reports a compensation-related award, not an open-market stock purchase. The code “A” and description show it is a grant of stock options, providing rights to buy shares later rather than an immediate acquisition of common stock in the market.

How many Corvus (CRVS) derivative securities does the director hold after this transaction?

After the grant, the Form 4 shows 15,000 stock options following the reported transaction. These options are derivative securities tied to 15,000 underlying shares of common stock and become exercisable only after the specified vesting conditions are satisfied.